Maranhão M F, de Castro I, Albanesi Filho F M, Bozza A, de Brito A X, Sbissa A S
Hospital das Clínicas da Universidade Federal do Paraná, Curitiba, PR.
Arq Bras Cardiol. 1992 Feb;58(2):149-55.
To evaluate the efficacy of diltiazem versus placebo in patients with stable angina.
Eight-seven angina pectoris patients, mean age of 57 +/- 9, 82 white and 79 male were evaluated in a randomized, double-blind trial of two groups of patients diltiazem and placebo, 3 to 4 tablets a day (diltiazem 180 to 240 mg daily). The patients were evaluated after laboratory tests and clinical-ergometric examinations. A coronary arteriography was performed on study entry.
The average of anginal attacks, number of weekly sublingual nitrate, heart rate, systolic and diastolic pressure at rest and at the end of diltiazem period were significantly lower (p < 0.05) regarding same periods on placebo. The percentage of depression for ST-segment was lower for diltiazem when compared with placebo (p < 0.05) and the percentage of patients that reach higher stages in the ergometric test was significantly better for diltiazem. Heart rate and systolic plus diastolic pressures after exercise did not differ in both groups.
Diltiazem reduced the clinical and electrocardiographical aspects and raises the effort tolerance during the ergometric test in patients with stable angina.
评估地尔硫䓬与安慰剂对稳定型心绞痛患者的疗效。
在一项随机、双盲试验中，对87例心绞痛患者进行评估，患者平均年龄57±9岁，其中82例为白人，79例为男性，分为地尔硫䓬组和安慰剂组，每日服用3至4片（地尔硫䓬每日180至240毫克）。在实验室检查和临床运动试验后对患者进行评估。研究开始时进行冠状动脉造影。
与安慰剂同期相比，地尔硫䓬治疗期间的平均心绞痛发作次数、每周舌下含服硝酸酯类药物的次数、静息及地尔硫䓬治疗结束时的心率、收缩压和舒张压均显著降低（p<0.05）。与安慰剂相比，地尔硫䓬治疗时ST段压低的百分比更低（p<0.05），且在运动试验中达到更高阶段的患者百分比，地尔硫䓬组明显更好。两组运动后的心率以及收缩压与舒张压之和无差异。
地尔硫䓬可改善稳定型心绞痛患者的临床及心电图表现，并提高运动试验中的运动耐量。
